Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Food Recall Warning - Certain Kinder brand chocolate products recalled due to possible Salmonella


Product photos are available: https://recalls-rappels.canada.ca/en/alert-recall/certain-kinder-brand-chocolate-products-recalled-due-possible-salmonella

OTTAWA, ON, April 6, 2022 /CNW/ -

Summary
Affected products

Brand

Product

Size

UPC

Codes

Kinder

Schoko-Bons

200 g

0 62020 02763 4

 

 

Best before dates from

September 3, 2022 to

October 17, 2022

Kinder

Happy Moments -

Kinder Confections Assortment

191 g

0 62020 01575 4

 

Best before July 23, 2022

Kinder

Mini Eggs

110 g

0 62020 02582 1

 

Best before dates from

July 14, 2022 to

August 18, 2022

Kinder

Mini Eggs

182 g

0 62020 02576 0

 

Best before dates from

July 12, 2022 to

September 3, 2022

Kinder

 

Mix - Egg Hunt Kit

186 g

0 62020 01627 0

 

Best before dates from

July 1, 2022 to

July 8, 2022

Kinder

Mix - Egg Hunt Kit

186 g

0 62020 01629 4

 

Best before dates from

July 1, 2022 to

July 8, 2022

Kinder

Mix - 7 Easter treats

116 g

0 62020 01616 4

 

Best before dates from

June 19, 2022 to

August 23, 2022

Kinder

Surprise, Miraculous

100 g

0 62020 02603 3

 

 

Best before dates from

August 19, 2022 to

October 28, 2022

Kinder

Surprise, Natoons

100 g

0 62020 02572 2

 

Best before dates from

August 29, 2022 to

October 28, 2022

Kinder

Surprise

100 g

0 62020 02625 5

 

Best before November 29, 2022

 
Issue

Ferrero Canada Ltd. is recalling certain Kinder brand chocolate products from the marketplace due to possible Salmonella contamination.

The recalled products have been sold nationally.

What you should do

Food contaminated with Salmonella may not look or smell spoiled but can still make you sick. Young children, pregnant women, the elderly and people with weakened immune systems may contract serious and sometimes deadly infections. Healthy people may experience short-term symptoms such as fever, headache, vomiting, nausea, abdominal cramps and diarrhea. Long-term complications may include severe arthritis.

Learn more:

Background

This recall was triggered by the company.

There have been no reported illnesses associated with the consumption of these products in Canada.

What is being done

The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated food recall warnings.

The CFIA is verifying that industry is removing the recalled products from the marketplace.

 Également disponible en français

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: